UvA Ventures Holding
UvA Ventures Holding BV, established in 1992 and based in Amsterdam, focuses on translating scientific innovations and expertise from the University of Amsterdam into marketable solutions. The company plays a crucial role in the university's valorisation objective by establishing or participating in various ventures and thereby promoting entrepreneurship. UvA Ventures engages in contract research and services, manages equity interests, and invests in early-stage companies characterized by novel technological innovations and significant growth potential. In addition to its investment activities, UvA Ventures provides governance, financial control, management, and advisory services to its portfolio companies, as well as to affiliated entities such as AMC Ventures Holding BV and HvA Ventures Holding BV associated with the Academic Medical Center and the Hogeschool van Amsterdam.
12 past transactions
Anywyse
Seed Round in 2023
Anywyse is an audio learning platform that focuses on facilitating skill acquisition through convenient, bite-sized audio content. It allows users to learn while engaging in daily activities such as driving, exercising, or performing household chores. The platform offers small audio fragments on a wide range of topics, making it easier for learners to absorb information efficiently. This approach not only saves time but also enhances the learning experience, enabling students to prepare effectively for exams and acquire new skills in a flexible and accessible manner.
Kepler Vision Technologies
Seed Round in 2020
Kepler Vision Technologies is a technology company specializing in artificial intelligence and computer vision aimed at improving care in elder care centers and healthcare facilities. The company has developed the "Kepler Night Nurse" application, which utilizes deep learning to monitor live video streams and detect incidents that may require caregiver intervention. This innovative software effectively reduces false alarms and minimizes reporting tasks for caregivers, allowing them to concentrate on providing direct care to clients. As the demand for elder care continues to rise, Kepler addresses the challenges of staff retention and workload pressure in the industry. Founded as a spin-off from the University of Amsterdam, Kepler Vision Technologies is dedicated to enhancing the efficiency and effectiveness of care delivery.
ACE Incubator
Seed Round in 2018
ACE Incubator is a university startup incubator based in Amsterdam, jointly owned by four academic institutions: the University of Amsterdam, Vrije Universiteit, Hogeschool van Amsterdam, and Amsterdam UMC. It is dedicated to supporting researchers, scientists, students, and entrepreneurs with technology-driven ideas, helping them transform their concepts into viable businesses. The incubator hosts young entrepreneurs who are developing innovative solutions in sectors such as deep tech, medical and health technology, chemical and advanced materials, and sustainable technology. ACE provides a range of resources, including tailored programs, startup facilities, an extensive entrepreneurial network, and mentorship from experienced startup professionals, thereby facilitating the growth of ambitious science and high-tech entrepreneurs at all stages of their business journey.
Kepler Vision Technologies
Seed Round in 2018
Kepler Vision Technologies is a technology company specializing in artificial intelligence and computer vision aimed at improving care in elder care centers and healthcare facilities. The company has developed the "Kepler Night Nurse" application, which utilizes deep learning to monitor live video streams and detect incidents that may require caregiver intervention. This innovative software effectively reduces false alarms and minimizes reporting tasks for caregivers, allowing them to concentrate on providing direct care to clients. As the demand for elder care continues to rise, Kepler addresses the challenges of staff retention and workload pressure in the industry. Founded as a spin-off from the University of Amsterdam, Kepler Vision Technologies is dedicated to enhancing the efficiency and effectiveness of care delivery.
Macrobian Biotech
Pre Seed Round in 2017
Macrobian Biotech is a developer of healthcare treatments focused on disorders that impact the midbrain dopamine system. The company engages in fundamental and clinical research within the neuroscience field, utilizing advanced technologies in genetics and transcriptomics, as well as extensive gene function research. This approach enables Macrobian Biotech to develop clinical trial-ready compounds aimed at treating various neurological and neuropsychiatric diseases, providing healthcare practitioners with innovative solutions for managing these complex disorders.
Confocal.nl
Pre Seed Round in 2016
Confocal.nl is aiming to innovate the microscopy industry with their plug-and-play feature confocal microscopes including the re-scan invention (Re-scan Confocal Microscope). Their new RCM-microscope has an improved resolution and strongly improved sensitivity as compared to most confocal microscopes. It will be available as a highly affordable, customised device, which is ideal for labs with specific interests, or as an upgrade for existing wide-field fluorescence microscopes. Their goal is an open-architecture system that can be customised at need, and is platform- and software independent.
Haermonics
Seed Round in 2015
Haermonics develops a medical device designed to prevent blood-related complications following open-heart surgery. Its innovative flushing therapy reduces blood loss and the need for re-operations, enabling healthcare providers to enhance patient recovery and lower hospital costs.
Raydiant Europe
Pre Seed Round in 2013
Raydiant Europe, an AI-focused company spun off from the University of Amsterdam, specializes in developing proprietary software solutions for face analysis and recognition. Utilizing advanced computer vision and deep learning technologies, Raydiant Europe provides tools that enable the anonymous analysis of faces in various contexts, including images, videos, and real-world environments. Their software offers businesses accurate and actionable insights into audience behavior while facilitating secure identity verification and user authentication across multiple applications, such as access control, Know Your Customer (KYC) processes, and payment verification. This enables developers to seamlessly integrate face analysis capabilities into their applications in a cost-effective manner.
Sigmascreening
Seed Round in 2010
Sigmascreening B.V. is a medical device company based in Amsterdam, Netherlands, specializing in the development of innovative products for breast cancer screening. Established in 2010 as a spin-off from the Academic Medical Center Amsterdam, Sigmascreening focuses on enhancing digital mammography, the recognized standard for breast cancer detection. One of its notable products is the Sensitive Sigma Paddle, designed to measure the mechanical properties of breast tissue during compression, thereby improving the accuracy and effectiveness of screening processes. The company is committed to advancing technology in the field of breast cancer diagnostics through its ongoing product development efforts.
InCatT
Seed Round in 2009
InCatT specializes in contract research for catalyst development, serving various industries such as pharmaceuticals, flavors & fragrances, oil & gas, and fine chemicals. The company offers services including high-throughput screening, catalyst optimization, and scale-up studies.
Photanol
Pre Seed Round in 2008
Photanol develops technology converting CO2 and sunlight into valuable organic compounds. It targets markets like food ingredients, chemical bio-blocks, and bio-fuels.
Arthrogen B.V.
Seed Round in 2005
Arthrogen is a biopharmaceutical company based in Amsterdam that focuses on developing local gene therapy for inflammatory diseases. The company utilizes viral-mediated gene transfer, specifically adeno-associated virus (AAV)-based therapeutics, to address various health conditions. Its primary emphasis is on treating rheumatic diseases, aiming to provide effective solutions for managing these inflammatory disorders. By specializing in the creation of viral gene therapy vectors, Arthrogen seeks to advance treatment options for health professionals dealing with inflammatory diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.